Stay updated with breaking news from Liability Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October...
~ Strong PEDMARK® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~ ~ PEDMARK® Permanent J-Code Effective April 1, 2023 ~ ~ Recent Positive CHMP Opinion in EU... | May 11, 2023
~ U.S. Commercial Team in Place with PEDMARK® Launch Off to Solid Start Following FDA Approval of PEDMARK® in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ ... | March 30, 2023
Caution Concerning Forward-Looking Statements The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated... | March 29, 2023
(2022-11-11 | TSX:FRX) Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update